Table 2.
Summary of susceptibility and disease outcome studies performed in MS patients and controls in relation to genetic variation in the iron-related SLC11A1 and HFE genes
| Gene | Country | Study size | Association | References |
|---|---|---|---|---|
| SLC11A1 | South Africa | 104 MS patients, 522 controls including 32 parental alleles as family-based controls | Yes | Kotze et al. 2001 |
| Spain | 195 MS patients, 125 controls | No | Comabella et al. 2004 | |
| Sardinia | 66 MS patients, 60 controls | Yes | Gazouli et al. 2008 | |
| Turkey | 100 MS patients, 100 controls | No | Ates et al. 2010 | |
| HFE | Tasmania | 166 MS families, 489 MS patients, 104 control families | No clinical, despite 3-fold increase of C282Y in MS | Rubio et al. 2004 |
| Slovenia | 314 MS patients, 400 controls | No, although earlier onset of MS symptoms noted in C282Y carriers | Ristic et al. 2005 | |
| South Africa | 118 MS patients, 102 controls | No, although two sisters with MS (without HH) were C282Y++ | Kotze et al. 2006 | |
| UK | 112 benign and 51 malignant MS patients | No | Ramagopalan et al. 2008a, b | |
| Portugal | 373 MS patients | No, although MS patients with mutation C282Y had a worse prognosis | Bettencourt et al. 2011 |
HH hereditary hemochromatosis